The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

The drug had already failed in two phase 3 trials in 2012 – but Lilly pressed on with a third trial in mild Alzheimer’s after spotting a trend in the data suggesting an effect in a small group ...

The EU medicines regulator on Friday rejected Eli Lilly's (LLY.N), opens new tab Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the ...

European Committee Says Lilly Alzheimer's Drug Shouldn't Get Marketing Approval A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over ...

European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should ... a greater risk that patients taking the drug would experience ARIA.

A European health committee has rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is already ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Lilly said Friday that it hopes discussions about the drug continue with the agency ... that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.

that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit. Shares of Eli Lilly ...